Elligo and Partners Participate in Federal Real-World Evidence Project

Austin, Texas, June 19, 2018 — Elligo Health Research, which offers the only platform that brings clinical research direct to clinical health care, announces that Flatiron Health and the University of Chicago have agreed to act as data partners in a federal project led by the FDA to develop and pilot a common data architecture. This common architecture will serve as the intermediary between various data sources, thereby streamlining patient-centered research using de-identified or aggregated data from the delivery of health care in routine clinical settings.

Elligo is leading an effort to test the FDA harmonization model, a part of the common data architecture. Its partners, using a variety of electronic health record systems, will provide de-identified or aggregated datasets for the safety assessment of new oncology therapies.

“Our goal at Elligo is not just to facilitate research,” said John Potthoff, PhD, CEO of Elligo Health Research. “We embrace the opportunity to bring these companies together to work toward better data usability and patient outcomes.”

“Clinical research drives progress in oncology,” said Sam Volchenboum, MD, PhD, MS, associate professor of pediatrics and the director of the Center for Research Informatics at the University of Chicago Medicine. “This project will speed the conversion of de-identified research study data to make it more useful for the development of much-needed therapies.”

“Our electronic health record (EHR) systems are specifically designed for oncology providers and patients,” said Amy Abernethy, MD, PhD, chief medical officer and chief scientific officer, Flatiron Health. “By participating in this effort, we hope to advance standards that make the data more accessible for researchers to analyze and ultimately accelerate the development of cancer therapies.”

Mitra Rocca, the FDA’s associate director of medical informatics and the FDA lead on the harmonization project, will chair a session that covers the use of real-world data, including EHR data, on Tuesday, June 26, at the Drug Information Association (DIA) 2018 Global Annual Meeting in Boston.

 

About Elligo
Elligo Health Research offers the only platform that brings clinical research to physician practices, accelerating the development of new pharmaceutical, biotechnology and medical device products and therapies. Our Goes Direct® approach uses state-of-the-art technology to compliantly leverage current electronic health record data and applies a proprietary, prescreening process to match protocol-eligible patients for participation in clinical studies. It is our mission to support health care providers by providing personnel, procedures, technology and infrastructure for clinical research, enabling patients to participate in research while remaining under the care of their own trusted physician. Learn more at elligodirect.com.

Elligo Health Research Announces Acquisition of ePatientFinder Clinical Trial Exchange Technology Platform and Practice Network

Austin, Texas, May 24, 2018 — Elligo Health Research, which improves clinical trial access by engaging the 97 percent of physicians currently not offering clinical research to their patients, has acquired ePatientFinder’s Clinical Trial Exchange technology platform and referring practice network, which is the largest of its kind.

This acquisition will enhance Elligo’s trial matching process by incorporating ePatientFinder’s technology platform. Using this platform, Elligo will streamline patient identification and feasibility through automation using electronic health record (EHR) data within Elligo’s network of providers.

“We believe this is an important strategic opportunity for Elligo to expand our technology and network growth capabilities,” said John Potthoff, PhD, CEO of Elligo Health Research. “ePatientFinder provides a technology platform and partnership ecosystem that will enable us to automate our EHR data analytics capabilities and expand our network of Research Ready™ sites to further benefit physicians, patients and sponsors.”

Elligo implements its Goes Direct® approach to provide physicians with the personnel, procedures, technology and infrastructure to conduct trials in Research Ready™ sites. This makes clinical trials more efficient and cost-effective, allowing patients to gain access to treatment options, enabling physicians to avoid the expenditure and effort of managing in-house infrastructure, and making it easier for sponsors to bring new therapies to market faster.

About Elligo
Elligo Health Research offers the only platform that brings clinical research to physician practices, accelerating the development of new pharmaceutical, biotechnology and medical device products and therapies. Our Goes Direct® approach uses state-of-the-art elliGO DIRECT™ technology to compliantly leverage current electronic health record data and applies a proprietary, prescreening process to match protocol-eligible patients for participation in clinical studies. It is our mission to support health care providers by providing personnel, procedures, technology and infrastructure for clinical research, enabling patients to participate in research while remaining under the care of their own trusted physician. Learn more at elligodirect.com.

Research Ready™ Program Expands and Diversifies Clinical Trial Patient Populations

Austin, Texas, May 15, 2018 — Elligo Health Research, which improves clinical trial access by engaging the 97 percent of physicians currently not offering clinical research to their patients, has launched a Research Ready™ program for physician practices interested in becoming a study site. Through the program, health care providers are able to offer clinical research studies as a care option to their patients. As a result, patient participation and retention rates increase, contributing to a more diverse population of patients and subsequently enabling clinical research organizations (CROs) and sponsors to get their studies up and running faster.

The Research Ready™ program is part of Elligo’s Goes Direct® approach, which provides a larger patient pool, more randomizations and better retention by making clinical research studies accessible to physicians and their patients. Through the program, physician practices are evaluated on a number of study-related components and are provided the technology, the infrastructure and a clinical coordinator to perform trials.

“We know patient diversification is important for our trial sponsors and CROs,” said John Potthoff, Ph.D., CEO of Elligo. “We make it easier for more patients to participate in trials through their own trusted physician. And, not only are our sites benefiting from the infrastructure support, but our sponsors and CROs are getting quality study data from community practice researchers.”

Every research site conducting research with Elligo has received the Research Ready™ designation. Currently, Elligo has more than 200 physician partners — with specialization in women’s health, gastroenterology, urology and pain management indications.

About Elligo Health Research
Elligo Health Research offers the only platform that brings clinical research to physician practices, accelerating the development of new pharmaceutical, biotechnology and medical device products and therapies. Our Goes Direct® approach uses state-of-the-art elliGO DIRECT™ technology to compliantly leverage current electronic health record data and applies a proprietary, prescreening process to match protocol-eligible patients for participation in clinical studies. It is our mission to support health care providers by providing personnel, procedures, technology and infrastructure for clinical research, enabling patients to participate in research while remaining under the care of their own trusted physician. Learn more at elligodirect.com.

Elligo Health Research Raises $16M to Improve Access to Clinical Trials

Austin, Texas, March 20, 2018 — Elligo Health Research, which improves clinical trial access by engaging the 97 percent of physicians currently not offering clinical research to their patients, announced today $16 million in Series B funding led by Hatteras Venture Partners and Noro-Moseley Partners with participation from FS Healthcare LLC, Excelerate Health Ventures and all existing Series A investors including Shumway Capital.

“In a short time Elligo has clearly shown that their approach improves access to clinical trials,” said John Crumpler, general partner at Hatteras Venture Partners. “We believe they will build on their current successes and continue to drive positive changes in the health care industry.”

“Our programs speak specifically to the medical practices that are hesitant to perform research in their offices due to lack of resources and infrastructure,” said John Potthoff, Ph.D., CEO of Elligo. “The new funding will help us expand our services and not only make research studies more accessible to physician sites but also streamline data collection and submission processes.”

“We look for opportunities to support entrepreneurs who excel within their industries,” said Allen Moseley, managing general partner at Noro-Moseley Partners. “Elligo’s team has the drive to effect change and the expertise to develop robust processes and technologies to significantly improve the clinical trial process.”

“The investment will enable us to accelerate expansion of our network of physicians and refine our technology platform to improve study efficiency,” said Chad Moore, president of Elligo. “And, every day we are one step — one study, one patient, one physician — closer to fulfilling our mission of improving clinical research and bringing new treatments to market faster by making it easier for physicians and patients to participate.”

 

About Elligo
Elligo Health Research offers the only platform that brings clinical research to the clinic, accelerating the development of new pharmaceutical, biotechnology and medical device products and therapies. Elligo Goes Direct® with an approach that uses electronic health records and other health data to identify real-world patients and physicians for participation in clinical studies. It is our mission to support health care providers by providing personnel, procedures, technology and infrastructure for clinical research, enabling patients to participate in research while remaining under the care of their own trusted physician. Learn more at elligodirect.com.

Elligo Health Research and Saama Technologies Announce Strategic Partnership to Advance Clinical Research Data Management

Austin, Texas, and Campbell, Calif., Feb. 28, 2018 Elligo Health Research, which improves clinical trial access by engaging the 97 percent of physicians currently not offering clinical research to their patients, is partnering with Saama Technologies, Inc., a leading clinical data analytics company, to improve awareness of, access to, and participation in clinical trials for U.S. physicians and patients.

“We are excited to work with Saama to develop an innovative technology platform to transform the clinical research process overall, from standards-based data collection to eSubmissions to regulatory agencies,” said John Potthoff, Ph.D., Elligo CEO.

Through its Goes Direct® model, Elligo engages physicians and their patients by first identifying patients using electronic health records and then providing their physicians with the infrastructure to conduct the research in their own offices at no cost to them. Saama’s award-winning Life Science Analytics Cloud, powered by its unique, AI-enabled Fluid Analytics Engine, includes the Cohort Builder and Trial Planning Optimizer solutions, which facilitate the identification of patient populations based on clinical trial eligibility requirements.

“Saama and Elligo have each pioneered innovative solutions that positively disrupt and improve the clinical trial landscape,” said Suresh Katta, founder and CEO of Saama. “Together, Saama and Elligo will set a new bar for physician and patient access to, and engagement with, clinical research that may improve patients’ health, enhance physicians’ understanding of disease management, and expand medical knowledge for treating some of the most prevalent and devastating human diseases.”

The partnership will help resolve the challenges sponsors face when they must assemble vast amounts of data from disparate sources.

“Saama’s groundbreaking analytics can deliver aggregated operational and clinical data to provide a multidimensional and real-time view of even multi-site trials,” Katta said. “By combining our life sciences solutions with Elligo’s unique approach and clinical research experience, we can improve data management to support accelerated research and development of meaningful therapeutics.”

“With Saama as a partner, Elligo will continue to improve access to standards-based eSource data directly from clinical research sites,” Potthoff added.

Meet with Saama and Elligo at the upcoming Bridging Clinical Research & Clinical Health Care Collaborative, April 4–5 in National Harbor, Md.

 

About Elligo
Elligo Health Research offers the only platform that brings clinical research to the clinic, accelerating the development of new pharmaceutical, biotechnology and medical device products and therapies. Elligo Goes Direct® with an approach that uses electronic health records and other health data to identify real-world patients and physicians for participation in clinical studies. Elligo supports health care providers by providing personnel, procedures, technology and infrastructure for clinical research, enabling patients to participate in research while remaining under the care of their own trusted physician. Learn more at elligodirect.com.

About Saama
Saama Technologies is the advanced data and analytics company delivering actionable business insights for life sciences and the Global 2000. Saama is singularly focused on driving fast, flexible, impactful business outcomes for clients through data and analytics. Saama’s unique “hybrid” approach integrates focused solutions and expertise across the life sciences domain, business consulting, data science, automated data management, and big data technologies. Saama integrates manual and disconnected initiatives into a well-aligned roadmap, facilitating the client’s journey from strategy through solution implementation.

Elligo Health Research and PatientLink Partnership Brings New Opportunities for Physicians and Their Patients

Austin, Texas, Nov. 9, 2017 — Elligo Health Research, a leading clinical research infrastructure provider that brings together sponsors, physicians, patients and CROs to improve clinical trial access and efficiency, is now connecting physicians and patients to treatment options through a new partnership with PatientLink Enterprises, an innovative medical patient data collection and enrollment software development company.

To benefit its customers who are ready to bring clinical studies to their practice, PatientLink is recommending Elligo’s Goes Direct® approach. The relationship connects physicians who are interested in research with the resources and infrastructure needed to make it possible.

“Introducing select clients to Elligo has allowed us to further fulfill our mission of connecting people to people — first patients to physicians with our electronic health record (EHR) solutions and now physicians to research with Elligo,” said Debi Willis, CEO and founder of PatientLink. “We are grateful to play a role in engaging physicians and patients in the research that will help uncover ways to live better and longer.”

“We are delighted to be advancing the care PatientLink’s physicians offer to their patients,” said Keith Fern, chief commercial officer at Elligo. “This opportunity will allow us to increase patient access to cutting edge clinical research by putting it in the hands of even more physicians. This is a win for everyone — for patients, for clinicians and for trial sponsors.”

About Elligo
Elligo Health Research offers the only platform that brings clinical research to the clinic, accelerating the development of new pharmaceutical, biotechnology and medical device products and therapies. Elligo Goes Direct®with an approach that uses electronic health records and other health data to identify real-world patients and physicians for participation in clinical studies. Elligo supports health care providers by providing personnel, procedures, technology and infrastructure for clinical research, enabling patients to participate in research while remaining under the care of their own trusted physician. Learn more at elligodirect.com.

About PatientLink
PatientLink’s core goal is to improve health and improve patient centered care, by providing multiple ways to collect and share important information between patients and their care givers. PatientLink supplies health organizations with customized software to gather their specific data needs in the day-to-day care for patients. And because every patient is unique and important, PatientLink offers multiple modes for patients to share their information from home or from the office. PatientLink works with many health care organizations, EHR vendors, universities and government entities to enable the best patient and provider experience in data sharing. Earlier this year, PatientLink won first place in the ONC’s prestigious 2017 Consumer Health Data Aggregator Challenge.

Elligo Health Research Joins the BlueCloud Network

Austin, Texas, Oct. 24, 2017 — HealthCarePoint (HCP), a Texas-based health care and clinical research networking-technology company founded by patient survivors, today announced its mutual collaboration with Elligo Health Research. The collaboration will further both companies’ shared mission of positively transforming clinical research by improving efficiency and transparency.

HealthCarePoint will provide Elligo private VIP opt-in access to the BlueCloud® network, and, by deploying its BlueCloud cluster technology, Elligo also improves its current efforts in developing a network of investigator sites. This collaboration will improve transparency of regulatory, training and other certification documentation for Elligo’s health care professional (HCP) partners.

“With this networking technology, HCPs will have a central repository to keep their research related regulatory, training and other certification records,” said Keith Fern, Elligo’s Chief Commercial Officer. “It also enables Elligo and our sponsor customers access to this verified and secure information as needed to perform qualification visits and audits.”

Elligo will provide support to its sites within the BlueCloud network to ensure they take advantage of all the benefits BlueCloud makes possible. With support such as this — through its Goes Direct® approach — Elligo provides the infrastructure that makes it possible for physicians to conduct clinical research in their own clinics with their own patients.

“By adding HCP’s BlueCloud technology, we are able to improve our services to advance clinical trial conduct,” Fern added. “HCP shares our goals to bring more physicians and patients into clinical research by increasing trial efficiency as well as reduced cost and infrastructure.

“By developing and centralizing data in collaborative systems, health care professionals at all levels greatly benefit because they can share and access information in real time,” said Al Pacino, President at HealthCarePoint. “Many health care companies share similar goals with those in clinical research. BlueCloud is a technology that helps us to break down unnecessary barriers by empowering connectivity so that all stakeholders benefit and ultimately leave no patients behind.”

About Elligo Health Research:

Elligo Health Research offers the only platform that brings clinical research to the clinic, accelerating the development of new pharmaceutical, biotechnology and medical device products and therapies. Elligo Goes Direct®with an approach that uses electronic health records and other health data to identify real-world patients and physicians for participation in clinical studies. Elligo supports health care providers by providing personnel, procedures, technology and infrastructure for clinical research, enabling patients to participate in research while remaining under the care of their own trusted physician. Learn more at elligodirect.com.

About BlueCloud by HealthCarePoint:

BlueClouds are preferred destinations for healthcare and clinical research professionals, employers and stakeholder organizations. Nominated as one of the top innovations in the industry, BlueCloud® is the first independent (real-time/single sign-on) global Professional Network. A global collaborative network connects healthcare professionals and organizations in a secure, private system. It is comprised of various networks, including education, standards, technology, healthcare professionals, research sites, healthcare sites, schools and patients, that organize, centralize and share verifiable information for managerial and compliance activities. Available in over 162 countries, BlueClouds are used by over 1.3 million healthcare professionals from sponsors, CROs, research sites, hospitals and universities to thousands of healthcare and clinical research stakeholders. Saving the industry millions of dollars by eliminating redundancies, BlueClouds expedite study startup as well as ensure quality, transparency and compliance with the united mission of leaving no patient behind®.

 

Elligo Receives FDA Award to Evaluate Harmonized Data Model for Safety Assessment of New Oncology Therapies

Austin, Texas, Oct. 4, 2017Elligo Health Research, a leading clinical research infrastructure provider, has received an FDA award to evaluate the use of harmonized data models to gather real-world data, which will aid in the safety assessment of new oncology therapies.

While the U.S. Food and Drug Administration has already approved various cancer immunotherapies, the agency seeks to better understand their safety in a real-world setting. However, there are multiple ways to collect and represent data, and there is a lack of interoperability — the capability for systems to exchange and aggregate data from various sources. This leads to an inability to combine and analyze data, thus severely limiting its usefulness.

The FDA is leading a project to harmonize various data models so that important data can be more easily shared and interpreted. The resulting data architecture will allow data to be exchanged between existing data models. This approach will be tested by Elligo, using electronic health records as data sources.

“A data architecture and process that enable meaningful data exchange will allow us to leverage real-world evidence and patient experiences to accelerate learning,” said Rebecca Kush, Ph.D., Elligo’s scientific innovation officer. “Competing data models should not impede access to important information. We commend the FDA for spearheading this project.”

Having this data architecture facilitates data pooling for analysis, making it easier to support evidence-based care and increasing the value of patients participating in research studies.

“While the promise of real-world data for research is great, the ultimate value comes from being able to rapidly share high-quality data from electronic health records,” said Chad Moore, Elligo president. “We’re honored to be part of this project.”

About Elligo:
Elligo Health Research offers the only platform that brings clinical research to the clinic, accelerating the development of new pharmaceutical, biotechnology and medical device products and therapies. Elligo Goes Direct®with an approach that uses electronic health records and other health data to identify real-world patients and physicians for participation in clinical studies. Elligo supports health care providers by providing personnel, procedures, technology and infrastructure for clinical research, enabling patients to participate in research while remaining under the care of their own trusted physician. Learn more at elligodirect.com.

In-office research partnership calls on physician investigators

By Julie Quinn, MD, ELS

Elligo Health Research and Allscripts are partnering to create Elligo Goes Direct®, offering physicians the opportunity to participate in clinical research trials in their own offices and providing patients with convenient access to clinical trials.

Elligo Health Research provides clinical research infrastructure to healthcare clinics, in the form of people, services and technologies, to increase access to patients for clinical trials, while Allscripts maintains an electronic health record (EHR) system and other healthcare intelligence technologies to identify clinics and patients. Allscripts currently connects around 45,000 practices and 180,000 physicians with electronic healthcare resources. They also provide a patient engagement platform, which serves 7.2 million patients. Elligo is inviting sponsors and CROs to participate, offering access to patients and a more diverse, realistic population base.

Chad Moore, president of Elligo, described the reasons behind the formation of this partnership: “The companies share a common vision of providing innovative solutions to optimize clinical trials. This includes improving the speed and efficiency of trials and providing physicians and their patients easy access to new, developing therapies, while enabling revenue generating opportunities for physicians. … The Elligo-Allscripts partnership allows CROs, pharmaceutical, biotech and medical device companies access to the 97% of patients in healthcare settings that do not currently have access to clinical trials.”

Clinician users of the Allscripts EHR platforms will have access to the eParticipateSM service, facilitating participation in available trials after the EHR helps identify potential study subjects. Elligo will provide CRO infrastructure to the individual sites, including personnel and technology when needed, and an on-site manager for study activities. In order to participate, offices must be deemed “research-capable,” a term that Moore describes as encompassing “training, processes and technology.” Currently available studies involve the fields of gastroenterology, neurology, oncology, pain, pulmonology, urology and women’s health.

Research and direct patient care have traditionally been separate fields, with often less than ideal communication regarding shared patients. However, in recent years the idea of integrating research into patient care has received more attention. Patients like having access to cutting-edge treatments, and integrating the two fields can improve efficiency in both. In addition, the importance of real-world data is increasingly recognized in the clinical trial community. Bringing clinical research closer to the actual world inhabited by patients may mean that trials start gathering data and evaluating outcomes that are more meaningful to patients. The entire experience could become more integrated, with real-world clinical care practitioners identifying gaps in research and development.

A 2015 international survey conducted by the Center for Information & Study on Clinical Research Participation (CISCRP) found that 80% of patients are willing to participate in research studies, but the location of the research center plays a major role when these patients decide whether to actually participate, particularly for survey respondents from North America. While 83% of patients reported that their doctor’s recommendation strongly influences their decision to participate, only 18% of study participants reported first learning of their study through their physician’s office. Presumably, if physicians are more directly involved in research, they will have greater knowledge of available trials that may benefit their patients.

Jeff James, CEO of Wilmington Health, described the potential benefits of this approach: “Anything that can increase the awareness of clinical trials as a care option has the potential to be very positive for both the patient populations served and for the development process of new therapeutics. In this particular case, execution will determine if this model is sustainable. As long as the quality of the study can be maintained and the burden of conducting the studies is not prohibitive, then this has the opportunity to increase the participation of both patients and providers. It could help reduce the cost and time required to bringing a trial to completion.”

However, James added, “It is unclear whether this partnership will help adjust inclusion/exclusion criteria. It is feasible that it can, based on the patient data contained in the Allscripts database.”

Conducting selected trials in the familiar environment of a patient’s regular office, rather than sending patients off to a research center, has the potential to broaden the pool of patients available to participate in trials and should make it much easier for patients to participate once selected. The studies will still be conducted by CROs, but the researchers will now allow these remote sites to collect their data. This should expedite the development process for medications, devices and other therapies. In addition, sponsors benefit from data that represents a more real-world sample of study patients. Patients’ usual clinicians would be able to identify the most appropriate subjects for a given study, avoiding a common pitfall of direct marketing to patients. Physicians and nurses will be more actively engaged in the research process.

James noted, “Traditionally, training is required to become an investigator. This new model must contemplate that aspect. “

Receiving trial care under the same roof as usual care facilitates communication between the two areas and allows patients to obtain the benefits of study participation that they might otherwise not be able to receive (for example, if transportation to a study site is an issue). In addition, patients will be receiving care from a clinician that they already know and trust. At the same time, physicians who might otherwise have not gotten the chance to participate in clinical research can do so, improving their knowledge of developing therapies in their realm of expertise and decreasing their knowledge gap regarding available studies that may be appropriate for their patient population.

This partnership reflects a growing movement toward incorporating clinical care into research. By removing barriers to study participation and retention, patients and researchers benefit.

Moore said, “Elligo can improve the diversity in clinical research. Our Goes Direct approach empowers all qualifying patients with the ability to participate in research. Some healthcare providers in underserved communities don’t have relationships, connections or partnerships with sponsors or academic medical centers to enable their patients’ participation in research. The Elligo-Allscripts partnership is able to stratify patient populations to assist sponsors in designing, powering and conducting clinical research.”

The key component of this partnership is likening EHRs with clinical research. Previous attempts to integrate research and patient care have been critiqued for not incorporating EHRs. This new partnership addresses that criticism by making the EHR an integral part of study recruitment. In this aspect, the Elligo Goes Direct program joins other early adopters of EHR technology to identify study candidates, including the Mayo Clinic, the Holston Medical Group in Tennessee and the Research Institute of Deaconess Clinic in Indiana.

Download article (PDF)

Elligo Health Research Names Deirdre BeVard as Chief Operating Officer

Austin, Texas, Aug. 30, 2017 — Elligo Health Research, a leading clinical research infrastructure provider that brings together sponsors, physicians, patients and CROs to improve clinical trial access and efficiency, has hired Deirdre BeVard as chief operating officer.

BeVard’s innovative approaches to investigative site training, online site communities and adaptive study management will support Elligo’s Goes Direct® approach by removing barriers to patient participation and retention and simplifying participation in research studies. In addition, she will help physicians improve processes and conduct studies in their own clinics.

Over the past 25 years, BeVard has held leadership roles in clinical affairs and development operations. Most recently, she was vice president of development operations of Nektar Therapeutics. Responsible for clinical trial leadership, data management and outsourcing, she increased the company’s capacity to efficiently execute early- and late-stage trials.

BeVard is a member of the editorial board of Clinical Leader and is also the recipient of the HBA Rising Star Award from the Healthcare Businesswomen’s Association. A frequent conference speaker, BeVard will present Sept. 7 at DPharm in the Innovative Sources and Solutions track, with a presentation titled “Once Lost, Now Found: Discovering the last-mile solution to accessing patients in health care.”

“BeVard’s experience and passion for creating clinical trial efficiencies perfectly align with our core mission,” said John Potthoff, Ph.D., CEO of Elligo Health Research. “Through her analysis and fostering of productive stakeholder relationships, she will create environments that enhance the clinical trial process for sponsors, physicians and patients.”

To learn more about Elligo Health Research’s work in clinical research, visit Elligo at DPharm, Sept. 7-8 in Boston, in Booth #31 or elligodirect.com.

About Elligo:

Elligo Health Research offers the only platform that brings clinical research to the clinic, accelerating the development of new pharmaceutical, biotechnology and medical device products and therapies. Elligo Goes Direct®with an approach that uses electronic health records and other health data to identify real-world patients and physicians for participation in clinical studies. It is our mission to support health care providers by providing personnel, procedures, technology and infrastructure for clinical research, enabling patients to participate in research while remaining under the care of their own trusted physician. Learn more at elligodirect.com.